Navigation Links
Anti-rejection drug may increase risk of diabetes after kidney transplant

Washington, DC (Thursday, May 22, 2008) For patients undergoing kidney transplantation, treatment with the anti-rejection drug sirolimus may lead to an increased risk of diabetes, reports a study in the July Journal of the American Society of Nephrology (JASN).

"We demonstrated a robust association between sirolimus and diabetes after transplantation in a large group of kidney transplant recipients in the United States," comments Dr. John S. Gill of University of British Columbia, Vancouver. "The risk of diabetes was independent of other factors that are known to increase the risk of diabetes."

The researchers analyzed US Renal Data System data on approximately 20,000 Medicare beneficiaries undergoing kidney transplantation between 1995 and 2003. None of the patients had diabetes before their kidney transplant. Treatment with sirolimus was analyzed as a possible contributor to the risk of diabetes developing after transplantation, along with other known and potential risk factors.

"Sirolimus is a newer type of anti-rejection drug that has not been associated with diabetes in transplant recipients," Dr. Gill explains. "However, a number of animal studies and small clinical studies have suggested that sirolimus may increase the risk of diabetes."

The results suggested a higher rate of post-transplant diabetes among patients treated with sirolimus, compared to other anti-rejection drugs. Depending on which additional drugs they received, diabetes risk was 36 to 66 percent higher for patients receiving sirolimus.

Separate analysis of patients who stayed on the same anti-rejection drugs throughout the first year after transplantation showed similar results. The increase in risk was unrelated to any of the other drugs used in combination with sirolimus, or to other risk factors such as age, race/ethnicity, or obesity.

Diabetes is a serious and increasingly common complication occurring after kidney transplantation. "Patients who develop diabetes after transplantation have roughly the same risk of transplant failure as patients who develop acute transplant rejection," says Dr. Gill. Several factors are known to increase the risk of post-transplant diabetes, including some other anti-rejection drugs. The new report is the first large clinical study to suggest that sirolimus may be a risk factor as well.

"Further studies should be done to further clarify the risk of diabetes in sirolimus-treated patients," Dr. Gill adds. He also notes some important limitations of the study, including the fact that it was based on a review of previous data and limited to Medicare patients.


Contact: Shari Leventhal
American Society of Nephrology

Related medicine news :

1. Study provides hope that some transplant patients could live free of anti-rejection drugs
2. Smoking may strongly increase long-term risk of eye disease
3. Diabetes appears to increase risk of death for patients with acute coronary syndromes
4. Prophylactic cranial irradiation in small cell lung cancer significantly increases survival
5. Fat on chest and upper back increases risk of insulin resistance
6. Ability to cope with stress can increase good cholesterol in older white men, study finds
7. Handling Stress Properly Increases Good Cholesterol
8. High alcohol consumption increases stroke risk among Chinese men
9. High alcohol consumption increases stroke risk, Tulane study says
10. Increased distance to physician associated with thicker skin cancer at diagnosis
11. Genetic predisposition increases childhood asthma risk
Post Your Comments:
Related Image:
Anti-rejection drug may increase risk of diabetes after kidney transplant
(Date:10/13/2015)... Texas (PRWEB) , ... October 13, 2015 , ... ... treatment possible for children with autism, PediaPlex , a Southlake, Texas, child ... of ABA Therapy and educating military families about their options for ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... and eco-friendly home furnishings and décor, today announced it closed on a $20.5 ... The funds will be used to support the Company’s continued rapid growth and ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... team: Debbie Vereb has been named the organization’s Executive Vice President of ... have been hired to key leadership roles in the company. , Debbie Vereb’s ...
(Date:10/13/2015)... ... , ... Curly Hair Solutions® is thrilled to be a ... featuring the newest products and services to hit the market for women. With ... to unveil their recent partnership with Trade Secrets, a leading Canadian beauty retailer. ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... presented results from GyencoloGeneTM, the world’s first commercially-available next-generation sequencing laboratory test ... World Congress of Gynecology and Obstetrics in Vancouver, BC, Canada. , ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... YORK , Oct. 12, 2015 About ... Epilepsy refers to a spectrum of brain disorders manifested ... is caused by factors ranging from brain malformations and ... When the underlying cause of the disease is unidentified, ... is known as idiopathic epilepsy. An imbalance between the ...
(Date:10/12/2015)... 2015 --> --> ... by Product (Hand-held, Table-top, Desktop), Technology (Volume Measurement, Flow Measurement, ... - Global Forecast to 2020", published by MarketsandMarkets, the Spirometer ... at a CAGR of 9.8% from 2015 to 2020. ... igures spread th rough 187 P ages and ...
(Date:10/12/2015)... IRVINE, Calif. , Oct. 12, 2015  Edwards Lifesciences ... science of heart valves and hemodynamic monitoring, plans to announce ... after the market closes on Monday, October 26, 2015, and ... day to discuss those results. . A ... mobile devices by downloading Edwards, IR App for iPhone ...
Breaking Medicine Technology: